Cardiac gene therapy: Recent advances and future directions

Journal of Controlled Release

Volumn 215, Issue , 2015, Pages 101-111

  Mason, Daniel ^a   Chen, Yu Zhe ^a   Krishnan, Harini Venkata ^a   Sant, Shilpa ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b University of Pittsburgh   (United States)

Author keywords

Cardiovascular gene therapy; Non viral carriers; Viral carriers

Indexed keywords

CARDIOLOGY; DISEASE CONTROL; DISEASES; GENE TRANSFER;

CARDIO-VASCULAR DISEASE; CLINICAL TESTING; CURRENT STATUS; GENETIC INFORMATION; GENETIC MODIFICATIONS; NON-VIRAL CARRIERS; PLATFORM TECHNOLOGY; VIRAL CARRIERS;

GENE THERAPY;

ADENYLATE CYCLASE; DENDRIMER; GENE THERAPY AGENT; GRAPHENE; LIPOPLEX; POLYMER; POLYPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN A; VASCULOTROPIN A116A; VASCULOTROPIN C; VASCULOTROPIN D; VIRUS VECTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CELL CYCLE CHECKPOINT; CELL PROTECTION; GENE DELIVERY SYSTEM; GENE TARGETING; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; MULTICENTER STUDY (TOPIC); NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CARDIOVASCULAR DISEASES; GENE THERAPY; GENE TRANSFER; HEART DISEASES; PROCEDURES; TRENDS;

ANIMALS; CARDIOVASCULAR DISEASES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEART DISEASES; HUMANS;

EID: 84939140946     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.08.001     Document Type: Review

References (92)

1. A.H. Chaanine, J. Kalman, and R.J. Hajjar Cardiac gene therapy Semin. Thorac. Cardiovasc. Surg. 22 2010 127 139
2. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, M.J. Blaha, S. Dai, E.S. Ford, C.S. Fox, S. Franco, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, M.D. Huffman, S.E. Judd, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, R.H. Mackey, D.J. Magid, G.M. Marcus, A. Marelli, D.B. Matchar, D.K. McGuire, E.R. Mohler, C.S. Moy III, M.E. Mussolino, R.W. Neumar, G. Nichol, D.K. Pandey, N.P. Paynter, M.J. Reeves, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, C. American Heart Association Statistics, and S. Stroke Statistics Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association Circulation 129 2014 399 410
3. M.A. Laflamme, and C.E. Murry Heart regeneration Nature 473 2011 326 335
4. A.R. Lyon, M. Sato, R.J. Hajjar, R.J. Samulski, and S.E. Harding Gene therapy: targeting the myocardium Heart 94 2008 89 99
5. L.E. Vinge, P.W. Raake, and W.J. Koch Gene therapy in heart failure Circ. Res. 102 2008 1458 1470
6. M.A. Kay State-of-the-art gene-based therapies: the road ahead Nat. Rev. Genet. 12 2011 316 328
7. T. Sasano, K. Kikuchi, A.D. McDonald, S. Lai, and J.K. Donahue Targeted high-efficiency, homogeneous myocardial gene transfer J. Mol. Cell. Cardiol. 42 2007 954 961
8. D.S. Feldman, T.S. Elton, B. Sun, M.M. Martin, and M.T. Ziolo Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure Nat. Clin. Pract. Cardiovasc. Med. 5 2008 208 218
9. M.R. Bristow Beta-adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569
10. G. Tarone, J.L. Balligand, J. Bauersachs, A. Clerk, L. De Windt, S. Heymans, D. Hilfiker-Kleiner, E. Hirsch, G. Iaccarino, R. Knoll, A.F. Leite-Moreira, A.P. Lourenco, M. Mayr, T. Thum, and C.G. Tocchetti Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology Eur. J. Heart Fail. 16 2014 494 508
11. J. Tamargo, and J. Lopez-Sendon Novel therapeutic targets for the treatment of heart failure Nat. Rev. Drug Discov. 10 2011 536 555
12. J. Laakkonen, and S. Yla-Herttuala Recent advancements in cardiovascular gene therapy and vascular biology Hum. Gene Ther. 2015
13. S. Dimmeler, A.M. Zeiher, and M.D. Schneider Unchain my heart: the scientific foundations of cardiac repair J. Clin. Investig. 115 2005 572 583
14. E.D. Cohen, M.F. Miller, Z. Wang, R.T. Moon, and E.E. Morrisey Wnt5a and Wnt11 are essential for second heart field progenitor development Development 139 2012 1931 1940
15. Z. He, H. Li, S. Zuo, Z. Pasha, Y. Wang, Y. Yang, W. Jiang, M. Ashraf, and M. Xu Transduction of Wnt11 promotes mesenchymal stem cell transdifferentiation into cardiac phenotypes Stem Cells Dev. 20 2011 1771 1778
16. G. Heusch, K. Boengler, and R. Schulz Cardioprotection: nitric oxide, protein kinases, and mitochondria Circulation 118 2008 1915 1919
17. T. Miura, M. Tanno, and T. Sato Mitochondrial Kinase Signalling Pathways in Myocardial Protection from Ischaemia/Reperfusion-Induced Necrosis 2010
18. Y. Fujio, T. Nguyen, D. Wencker, R.N. Kitsis, and K. Walsh Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart Circulation 101 2000 660 667
19. M.-G. Perrelli, P. Pagliaro, and C. Penna Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species World J. Cardiol. 3 2011 186 200
20. H. Kim, H.A. Kim, Y.M. Bae, J.S. Choi, and M. Lee Dexamethasone-conjugated polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to cardiomyocytes J. Gene Med. 11 2009 515 522
21. R. Hinkel, P. Lange, B. Petersen, E. Gottlieb, J.K. Ng, S. Finger, J. Horstkotte, S. Lee, M. Thormann, M. Knorr, C. El-Aouni, P. Boekstegers, B. Reichart, P. Wenzel, H. Niemann, and C. Kupatt Heme oxygenase-1 gene therapy provides cardioprotection via control of post-ischemic inflammation: an experimental study in a pre-clinical pig model J. Am. Coll. Cardiol. 66 2015 154 165
22. A.M. Shah, and D.L. Mann In search of new therapeutic targets and strategies for heart failure: recent advances in basic science Lancet 378 2011 704 712
23. D. Rohde, M. Busch, A. Volkert, J. Ritterhoff, H.A. Katus, K. Peppel, and P. Most Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology Futur. Cardiol. 11 2015 309 321
24. P. Most, M. Boerries, C. Eicher, C. Schweda, P. Ehlermann, S.T. Pleger, E. Loeffler, W.J. Koch, H.A. Katus, C.A. Schoenenberger, and A. Remppis Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2) J. Biol. Chem. 278 2003 48404 48412
25. S.T. Pleger, P. Most, M. Boucher, S. Soltys, J.K. Chuprun, W. Pleger, E. Gao, A. Dasgupta, G. Rengo, A. Remppis, H.A. Katus, A.D. Eckhart, J.E. Rabinowitz, and W.J. Koch Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue Circulation 115 2007 2506 2515
26. S. Miyata, G. Takemura, K. Kosai, T. Takahashi, M. Esaki, L. Li, H. Kanamori, R. Maruyama, K. Goto, A. Tsujimoto, T. Takeyama, T. Kawaguchi, T. Ohno, K. Nishigaki, T. Fujiwara, H. Fujiwara, and S. Minatoguchi Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis Am. J. Pathol. 176 2010 687 698
27. G. Alloatti, E. Arnoletti, E. Bassino, C. Penna, M.G. Perrelli, C. Ghe, and G. Muccioli Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes Am. J. Physiol. Heart Circ. Physiol. 299 2010 H470 H481
28. Y. Ogura, N. Ouchi, K. Ohashi, R. Shibata, Y. Kataoka, T. Kambara, T. Kito, S. Maruyama, D. Yuasa, K. Matsuo, T. Enomoto, Y. Uemura, M. Miyabe, M. Ishii, T. Yamamoto, Y. Shimizu, K. Walsh, and T. Murohara Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models Circulation 126 2012 1728 1738
29. M. Lavu, S. Gundewar, and D.J. Lefer Gene therapy for ischemic heart disease J. Mol. Cell. Cardiol. 50 2011 742 750
30. D.W. Losordo, P.R. Vale, and J.M. Isner Gene therapy for myocardial angiogenesis Am. Heart J. 138 1999 S132 S141
31. M. Giacca, and S. Zacchigna VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond Gene Ther. 19 2012 622 629
32. K. Ishikawa, L. Tilemann, D. Ladage, J. Aguero, L. Leonardson, K. Fish, and Y. Kawase Cardiac gene therapy in large animals: bridge from bench to bedside Gene Ther. 19 2012 670 677
33. H.A. Kim, T. Rhim, and M. Lee Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy Adv. Drug Deliv. Rev. 63 2011 678 687
34. A.T. Askari, S. Unzek, Z.B. Popovic, C.K. Goldman, F. Forudi, M. Kiedrowski, A. Rovner, S.G. Ellis, J.D. Thomas, P.E. DiCorleto, E.J. Topol, and M.S. Penn Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet 362 2003 697 703
35. M.S. Penn, J. Pastore, T. Miller, and R. Aras SDF-1 in myocardial repair Gene Ther. 19 2012 583 587
36. U. Agarwal, W. Ghalayini, F. Dong, K. Weber, Y.R. Zou, S.Y. Rabbany, S. Rafii, and M.S. Penn Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction Circ. Res. 107 2010 667 676
37. R.J. Hajjar, K. Zsebo, L. Deckelbaum, C. Thompson, J. Rudy, A. Yaroshinsky, H. Ly, Y. Kawase, K. Wagner, and K. Borow Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure J. Card. Fail. 14 2008 355 367
38. A.M. Lompre, R.J. Hajjar, S.E. Harding, E.G. Kranias, M.J. Lohse, and A.R. Marks Ca2 + cycling and new therapeutic approaches for heart failure Circulation 121 2010 822 830
39. S. Sakata, D. Lebeche, N. Sakata, Y. Sakata, E.R. Chemaly, L.F. Liang, Y. Takewa, D. Jeong, W.J. Park, Y. Kawase, and R.J. Hajjar Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts Am. J. Physiol. Heart Circ. Physiol. 292 2007 H2356 H2363
40. F. del Monte, E. Williams, D. Lebeche, U. Schmidt, A. Rosenzweig, J.K. Gwathmey, E.D. Lewandowski, and R.J. Hajjar Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2 +)-ATPase in a rat model of heart failure Circulation 104 2001 1424 1429
41. Y. Zhang, A. Satterlee, and L. Huang In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol. Ther. 20 2012 1298 1304
42. Y. Zhang, A. Satterlee, and L. Huang In vivo gene delivery by nonviral vectors: overcoming hurdles[quest] Mol. Ther. 20 2012 1298 1304
43. K. Ishikawa, L. Tilemann, K. Fish, and R.J. Hajjar Gene delivery methods in cardiac gene therapy J. Gene Med. 13 2011 566 572
44. J.E. Ziello, Y. Huang, and I.S. Jovin Cellular endocytosis and gene delivery Mol. Med. 16 2010 222 229
45. S. Xiang, H. Tong, Q. Shi, J.C. Fernandes, T. Jin, K. Dai, and X. Zhang Uptake mechanisms of non-viral gene delivery J. Control. Release 158 2012 371 378
46. H.T. McMahon, and E. Boucrot Molecular mechanism and physiological functions of clathrin-mediated endocytosis Nat. Rev. Mol. Cell Biol. 12 2011 517 533
47. L. Kou, J. Sun, Y. Zhai, and Z. He The endocytosis and intracellular fate of nanomedicines: implication for rational design Asian J. Pharm. Sci. 8 2013 1 10
48. J.P. Gratton, P. Bernatchez, and W.C. Sessa Caveolae and caveolins in the cardiovascular system Circ. Res. 94 2004 1408 1417
49. C.H. Jones, C.-K. Chen, A. Ravikrishnan, S. Rane, and B.A. Pfeifer Overcoming nonviral gene delivery barriers: perspective and future Mol. Pharm. 10 2013 4082 4098
50. A.K. Varkouhi, M. Scholte, G. Storm, and H.J. Haisma Endosomal escape pathways for delivery of biologicals J. Control. Release 151 2011 220 228
51. J.K.W.L. Wanling Liang Endosomal escape pathways for non-viral nucleic acid delivery systems Mol. Regul. Endocytosis 17 2012 429 456
52. R. Cartier, and R. Reszka Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems Gene Ther. 9 2002 157 167
53. Y.E. Koshman, S.B. Waters, L.A. Walker, T. Los, P. de Tombe, P.H. Goldspink, and B. Russell Delivery and visualization of proteins conjugated to quantum dots in cardiac myocytes J. Mol. Cell. Cardiol. 45 2008 853 856
54. L. Tilemann, K. Ishikawa, T. Weber, and R.J. Hajjar Gene therapy for heart failure Circ. Res. 110 2012 777 793
55. C.R. Bridges, J.M. Burkman, R. Malekan, S.M. Konig, H. Chen, C.B. Yarnall, T.J. Gardner, A.S. Stewart, M.M. Stecker, T. Patterson, and H.H. Stedman Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation Ann. Thorac. Surg. 73 2002 1939 1946
56. W. Boecker, O.Y. Bernecker, J.C. Wu, X. Zhu, T. Sawa, L. Grazette, A. Rosenzweig, F. del Monte, U. Schmidt, and R.J. Hajjar Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter Mol. Imaging 3 2004 69 75
57. C.A. Pacak, and B.J. Byrne AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities Mol. Ther. 19 2011 1582 1590
58. M.S. Al-Dosari, and X. Gao Nonviral gene delivery: principle, limitations, and recent progress AAPS J. 11 2009 671 681
59. A. Ragusa, I. Garcia, and S. Penades Nanoparticles as nonviral gene delivery vectors IEEE Trans. Nanobioscience 6 2007 319 330
60. S.J. Gray, and R.J. Samulski Optimizing gene delivery vectors for the treatment of heart disease Expert. Opin. Biol. Ther. 8 2008 911 922
61. M.G. Katz, J.D. Swain, J.D. White, D. Low, H. Stedman, and C.R. Bridges Cardiac gene therapy: optimization of gene delivery techniques in vivo Hum. Gene Ther. 21 2010 371 380
62. O.J. Muller, H.A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc. Res. 73 2007 453 462
63. C. Zincarelli, S. Soltys, G. Rengo, W.J. Koch, and J.E. Rabinowitz Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart Clin. Transl. Sci. 3 2010 81 89
64. K. Inagaki, S. Fuess, T.A. Storm, G.A. Gibson, C.F. McTiernan, M.A. Kay, and H. Nakai Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8 Mol. Ther. 14 2006 45 53
65. N. Hammoudi, K. Ishikawa, and R.J. Hajjar Adeno-associated virus-mediated gene therapy in cardiovascular disease Curr. Opin. Cardiol. 30 2015 228 234
66. S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M.F. Montus, and C. Masurier Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors Hum. Gene Ther. 21 2010 704 712
67. P.E. Monahan, and R.J. Samulski Adeno-associated virus vectors for gene therapy: more pros than cons? Mol. Med. Today 6 2000 433 440
68. Y. Lai, Y. Yue, M. Liu, A. Ghosh, J.F. Engelhardt, J.S. Chamberlain, and D. Duan Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors Nat. Biotechnol. 23 2005 1435 1439
69. T. Wang, J.R. Upponi, and V.P. Torchilin Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies Int. J. Pharm. 427 2012 3 20
70. L. Jin, X. Zeng, M. Liu, Y. Deng, and N. He Current progress in gene delivery technology based on chemical methods and nano-carriers Theranostics 4 2014 240 255
71. J. Pelisek, M.G. Engelmann, A. Golda, A. Fuchs, S. Armeanu, M. Shimizu, C. Mekkaoui, P.H. Rolland, and S. Nikol Optimization of nonviral transfection: variables influencing liposome-mediated gene transfer in proliferating vs. quiescent cells in culture and in vivo using a porcine restenosis model J. Mol. Med. 80 2002 724 736
72. K. Ogawa, K. Tachibana, T. Uchida, T. Tai, N. Yamashita, N. Tsujita, and R. Miyauchi High-resolution scanning electron microscopic evaluation of cell-membrane porosity by ultrasound Med. Electron Microsc. 34 2001 249 253
73. L. Sun, C.W. Huang, J. Wu, K.J. Chen, S.H. Li, R.D. Weisel, H. Rakowski, H.W. Sung, and R.K. Li The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium Biomaterials 34 2013 2107 2116
74. J. Ji, S.Y. Ji, J.A. Yang, X. He, X.H. Yang, W.P. Ling, and X.L. Chen Ultrasound-targeted transfection of tissue-type plasminogen activator gene carried by albumin nanoparticles to dog myocardium to prevent thrombosis after heart mechanical valve replacement Int. J. Nanomedicine 7 2012 2911 2919
75. Y.T. Ko, W.C. Hartner, A. Kale, and V.P. Torchilin Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide Gene Ther. 16 2009 52 59
76. S. Yang, and S. May Release of cationic polymer-DNA complexes from the endosome: a theoretical investigation of the proton sponge hypothesis J. Chem. Phys. 129 2008 185105
77. Y. Lee, A.N. McGinn, C.D. Olsen, K. Nam, M. Lee, S.K. Shin, and S.W. Kim Human erythropoietin gene delivery for cardiac remodeling of myocardial infarction in rats J. Control. Release 171 2013 24 32
78. A. Paul, A. Hasan, H.A. Kindi, A.K. Gaharwar, V.T.S. Rao, M. Nikkhah, S.R. Shin, D. Krafft, M.R. Dokmeci, D. Shum-Tim, and A. Khademhosseini Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair ACS Nano 8 2014 8050 8062
79. Y.W. Won, A.N. McGinn, M. Lee, D.A. Bull, and S.W. Kim Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier Mol. Pharm. 10 2013 378 385
80. C. Dufes, I.F. Uchegbu, and A.G. Schatzlein Dendrimers in gene delivery Adv. Drug Deliv. Rev. 57 2005 2177 2202
81. S. Svenson, and D.A. Tomalia Dendrimers in biomedical applications - reflections on the field Adv. Drug Deliv. Rev. 57 2005 2106 2129
82. J. Liu, C. Gu, E.B. Cabigas, K.D. Pendergrass, M.E. Brown, Y. Luo, and M.E. Davis Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction Biomaterials 34 2013 3729 3736
83. H.Y. Nam, K. Nam, M. Lee, S.W. Kim, and D.A. Bull Dendrimer type bio-reducible polymer for efficient gene delivery J. Control. Release 160 2012 592 600
84. Y.W. Won, A.N. McGinn, M. Lee, K. Nam, D.A. Bull, and S.W. Kim Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia Biomaterials 34 2013 6229 6238
85. S. Goenka, V. Sant, and S. Sant Graphene-based nanomaterials for drug delivery and tissue engineering J. Control. Release 173 2014 75 88
86. B. Chen, M. Liu, L. Zhang, J. Huang, J. Yao, and Z. Zhang Polyethylenimine-functionalized graphene oxide as an efficient gene delivery vector J. Mater. Chem. 21 2011 7736 7741
87. L. Zhang, Z. Lu, Q. Zhao, J. Huang, H. Shen, and Z. Zhang Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide Small 7 2011 460 464
88. B.E. Jaski, M.L. Jessup, D.M. Mancini, T.P. Cappola, D.F. Pauly, B. Greenberg, K. Borow, H. Dittrich, K.M. Zsebo, and R.J. Hajjar I. Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease Trial, Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial J. Card. Fail. 15 2009 171 181
89. S. Rajagopalan, E. Mohler III, R.J. Lederman, J. Saucedo, F.O. Mendelsohn, J. Olin, J. Blebea, C. Goldman, J.D. Trachtenberg, M. Pressler, H. Rasmussen, B.H. Annex, and A.T. Hirsch Regional angiogenesis with vascular endothelial growth factor, regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial Am. Heart J. 145 2003 1114 1118
90. L. Favaloro, M. Diez, O. Mendiz, G.V. Janavel, L. Valdivieso, R. Ratto, G. Garelli, F. Salmo, M. Criscuolo, A. Bercovich, and A. Crottogini High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial Catheter. Cardiovasc. Interv. 82 2013 899 906
91. P.J. Halonen, J. Nurro, A. Kuivanen, and S. Yla-Herttuala Current gene therapy trials for vascular diseases Expert. Opin. Biol. Ther. 14 2014 327 336
92. N.C. Lai, D.M. Roth, M.H. Gao, T. Tang, N. Dalton, Y.Y. Lai, M. Spellman, P. Clopton, and H.K. Hammond Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure Circulation 110 2004 330 336